(KYMR) Kymera Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044
KYMR: IRAK4, STAT6, TYK2, Inflammation, Autoimmune, Small Molecule, PROTAC
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the discovery and development of small molecule therapeutics designed to selectively degrade disease-causing proteins. By leveraging the bodys inherent protein degradation system, Kymeras approach offers a novel and precise method to target specific proteins implicated in various diseases. The companys lead IRAK4 program is currently in Phase II clinical trials, focusing on treating immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis. Additionally, Kymera is advancing STAT6 for type 2 inflammation in allergic and atopic diseases and TYK2 to address autoimmune and inflammatory conditions. Founded in 2015, Kymera is headquartered in Watertown, Massachusetts, and is at the forefront of innovative drug development targeting protein degradation pathways.
Over the next three months, Kymera Therapeutics stock is expected to show short-term bullish momentum, supported by its recent price movement above the 20-day Simple Moving Average (SMA) of 27.13. However, the stock may face resistance near the 50-day SMA of 30.50 and the 200-day SMA of 40.81, indicating potential challenges in sustaining long-term upward movement. The Average True Range (ATR) of 2.21 suggests manageable volatility. Fundamentally, Kymeras market cap of $2.2 billion reflects investor confidence in its pipeline, despite a negative return on equity (RoE) of -26.79%, typical for a clinical-stage biotech company. The price-to-book (P/B) ratio of 2.61 and price-to-sales (P/S) ratio of 46.48 highlight the markets expectation of future growth, driven by its innovative approach and strategic focus on high-value therapeutic targets.
Additional Sources for KYMR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KYMR Stock Overview
Market Cap in USD | 2,297m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-08-21 |
KYMR Stock Ratings
Growth Rating | -19.3 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -9.42 |
Analysts | 4.53/5 |
Fair Price Momentum | 24.63 USD |
Fair Price DCF | - |
KYMR Dividends
No Dividends PaidKYMR Growth Ratios
Growth Correlation 3m | -52.3% |
Growth Correlation 12m | -29% |
Growth Correlation 5y | -31.2% |
CAGR 5y | -2.11% |
CAGR/Max DD 5y | -0.02 |
Sharpe Ratio 12m | 0.24 |
Alpha | -38.19 |
Beta | 2.092 |
Volatility | 94.92% |
Current Volume | 535.9k |
Average Volume 20d | 652.8k |
As of May 11, 2025, the stock is trading at USD 30.07 with a total of 535,923 shares traded.
Over the past week, the price has changed by -14.77%, over one month by +25.55%, over three months by -16.56% and over the past year by -22.12%.
Neither. Based on ValueRay Analyses, Kymera Therapeutics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -19.26 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KYMR as of May 2025 is 24.63. This means that KYMR is currently overvalued and has a potential downside of -18.09%.
Kymera Therapeutics has received a consensus analysts rating of 4.53. Therefor, it is recommend to buy KYMR.
- Strong Buy: 13
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, KYMR Kymera Therapeutics will be worth about 29.5 in May 2026. The stock is currently trading at 30.07. This means that the stock has a potential downside of -1.76%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 57.7 | 91.8% |
Analysts Target Price | 57.7 | 91.8% |
ValueRay Target Price | 29.5 | -1.8% |